NASDAQ:PAVM - Nasdaq - US70387R4039 - Common Stock - Currency: USD
NASDAQ:PAVM (5/30/2025, 8:25:12 PM)
0.6008
-0.01 (-2.39%)
The current stock price of PAVM is 0.6008 USD. In the past month the price decreased by -26.73%. In the past year, price decreased by -58.57%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.95 | 232.41B | ||
ISRG | INTUITIVE SURGICAL INC | 72.3 | 197.97B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.99 | 155.73B | ||
SYK | STRYKER CORP | 30.54 | 146.23B | ||
MDT | MEDTRONIC PLC | 15.09 | 106.43B | ||
BDX | BECTON DICKINSON AND CO | 12.25 | 49.47B | ||
EW | EDWARDS LIFESCIENCES CORP | 30.08 | 45.88B | ||
IDXX | IDEXX LABORATORIES INC | 45.03 | 41.60B | ||
RMD | RESMED INC | 26.96 | 35.89B | ||
DXCM | DEXCOM INC | 52 | 33.64B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.33 | 32.30B | ||
STE | STERIS PLC | 26.25 | 24.09B |
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The company went IPO on 2016-07-27. The firm operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
PAVMED INC
360 Madison Avenue, 25th Floor
New York City NEW YORK 10165 US
CEO: Lishan Aklog
Employees: 39
Phone: 12129494319
The current stock price of PAVM is 0.6008 USD. The price decreased by -2.39% in the last trading session.
The exchange symbol of PAVMED INC is PAVM and it is listed on the Nasdaq exchange.
PAVM stock is listed on the Nasdaq exchange.
8 analysts have analysed PAVM and the average price target is 11.99 USD. This implies a price increase of 1894.84% is expected in the next year compared to the current price of 0.6008. Check the PAVMED INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PAVMED INC (PAVM) has a market capitalization of 10.59M USD. This makes PAVM a Nano Cap stock.
PAVMED INC (PAVM) currently has 39 employees.
PAVMED INC (PAVM) has a support level at 0.58 and a resistance level at 0.63. Check the full technical report for a detailed analysis of PAVM support and resistance levels.
The Revenue of PAVMED INC (PAVM) is expected to decline by -95.85% in the next year. Check the estimates tab for more information on the PAVM EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PAVM does not pay a dividend.
PAVMED INC (PAVM) will report earnings on 2025-08-11.
The PE ratio for PAVMED INC (PAVM) is 0.68. This is based on the reported non-GAAP earnings per share of 0.88 and the current share price of 0.6008 USD. Check the full fundamental report for a full analysis of the valuation metrics for PAVM.
The outstanding short interest for PAVMED INC (PAVM) is 1.77% of its float. Check the ownership tab for more information on the PAVM short interest.
ChartMill assigns a fundamental rating of 3 / 10 to PAVM. PAVM may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months PAVM reported a non-GAAP Earnings per Share(EPS) of 0.88. The EPS increased by 109.85% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 3635.17% | ||
ROA | 137.15% | ||
ROE | 154.17% | ||
Debt/Equity | 0.14 |
ChartMill assigns a Buy % Consensus number of 83% to PAVM. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 72.05% and a revenue growth -95.85% for PAVM